The adjusted relative risk of major cardiovascular events in the participants with NASH (0.35, 95% CI 0.17–0.74) was less than half that of the participants without NASH (0.73, 95% CI 0.49–1.00), although this difference did not reach statistical significance [ 176 ].
← all excerpts
Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.
1
—
—